JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Neuroprotective Effects of Berberine in Alzheimer's Disease

Seema Sharma*[1], Inderpreet Kaur[2], Rupinder Kaur[3], Sampat Singh Tanwar[1]

[1] *Assistant Professor, Department of Pharmacy, Shri Vaishnav Institute of Pharmacy, Shri Vaishnav Vidyapeeth Vishwavidyalaya, Indore, Madhya Pradesh, India*
[2] *Assistant Professor, Department of Pharmacy, Shivalik College of Pharmacy, Nangal, Punjab, India*
[3] *Associate Professor, Department of Pharmacy, Sachdeva College of Pharmacy, Gharuan, Punjab, India*

Publication history: Received on 5th Mar 2025; Revised on 18th March 2025; Accepted on 19th March 2025

Article DOI: 10.69613/7nf68287

Abstract: Alzheimer's disease (AD) is one of the predominant causes of dementia worldwide. It is characterized by progressive neurodegeneration, cognitive decline, and distinctive neuropathological features including β-amyloid plaques and neurofibrillary tangles. Current therapeutic interventions provide only symptomatic relief, emphasizing the need for disease-modifying treatments. Berberine, an isoquinoline alkaloid derived from various medicinal plants, is being recognized as a promising treatment for AD treatment due to its diverse pharmacological properties. Recent studies have shown the berberine's ability to modulate multiple pathological processes in AD, including reduction of amyloid-β production, inhibition of tau hyperphosphorylation, enhancement of cholinergic transmission, and attenuation of oxidative stress and neuroinflammation. The capacity of berberine to cross the blood-brain barrier and its established safety profile further support its potential as a neurotherapeutic agent. Berberine acts by altering AMPK signaling, NF-ϰB regulation, and modulation of cholinergic systems. It also shows remarkable effects on mitochondrial function, synaptic plasticity, and neuronal survival. Additionally, berberine exhibits synergistic effects when combined with conventional AD treatments, suggesting its potential role in combination therapy.

Keywords: Alzheimer's disease; Berberine; Neuroprotection; AMPK pathway; Tau Proteins.

1. Introduction

Alzheimer's disease (AD) stands as one of the most devastating neurodegenerative disorders, affecting millions worldwide and posing a challenge to healthcare systems [1]. The disease is characterized progressive cognitive deterioration, with memory loss, behavioral changes, and eventual loss of independence in daily activities [2]. At the molecular level, AD pathology is characterized by two primary hallmarks: extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein [3, 4]. The pathogenesis of AD involves synaptic dysfunction, neuroinflammation, oxidative stress, and mitochondrial impairment [5]. Early symptoms often manifest as subtle cognitive changes and depression, typically appearing up to 12 years before clinical diagnosis in late-onset cases [6]. The disease progression follows a predictable pattern of neural degeneration, beginning in the entorhinal cortex and hippocampus before spreading to other brain regions [7].

Epidemiological data indicates a sharp increase in AD prevalence with age, with a higher incidence in females [8]. Current estimates suggest that AD cases will double every two decades, with a disproportionate increase expected in developing nations [9]. This projected surge emphasizes the urgent need for effective therapeutic interventions that can modify disease progression rather than merely managing symptoms. The limitations of current AD treatments have sparked intense interest in natural compounds with potential disease-modifying properties. Among these, berberine has emerged as a particularly promising candidate [10].

This isoquinoline alkaloid, traditionally used in various medical systems, demonstrates remarkable versatility in targeting multiple pathological processes involved in AD [11]. The main aim of this review is to present the molecular mechanisms associated with berberine's neuroprotective effects and evaluate the current literature available on AD treatment.

2. Pathophysiology of Alzheimer's Disease

AD pathophysiology is attributed to the accumulation of misfolded proteins, particularly Aβ and tau, which trigger a cascade of detrimental cellular events [12].

* Corresponding author: Seema Sharma

The molecular and cellular mechanisms that contribute to progressive neurodegeneration are:

2.1. Amyloid Plaques

The amyloid plaques begin with aberrant processing of amyloid precursor protein (APP) through the amyloidogenic pathway. This process, mediated by β- and γ-secretases, generates Aβ peptides of varying lengths, with Aβ42 being particularly prone to aggregation [13]. These peptides form oligomers and eventually mature into the characteristic amyloid plaques. The soluble oligomers, rather than the plaques themselves, are now considered the primary toxic species, disrupting synaptic function and triggering inflammatory responses [14].

2.2. Tau Proteins

Tau protein, normally involved in microtubule stabilization, undergoes abnormal hyperphosphorylation in AD. This modification leads to the formation of paired helical filaments and eventually neurofibrillary tangles [15]. The spread of tau pathology follows a predictable pattern through the brain, correlating strongly with cognitive decline and disease progression [16].

2.3. Neuroinflammation and Oxidative Stress

Chronic neuroinflammation represents a crucial component of AD pathophysiology. Activated microglia and astrocytes release pro-inflammatory mediators, creating a self-perpetuating cycle of inflammation [17]. Simultaneously, oxidative stress increases, overwhelming cellular antioxidant defenses and leading to mitochondrial dysfunction and cellular damage [18].

3. Berberine

3.1. Chemical Structure

Berberine ($C_{20}H_{18}NO_4^+$) is an isoquinoline alkaloid characterized by its distinctive yellow color and quaternary ammonium structure. Its molecular configuration enables interaction with multiple cellular targets, contributing to its diverse pharmacological effects [19].



Figure 1. Structure of Berberine

3.2. Pharmacokinetics

The compound has moderate oral bioavailability due to P-glycoprotein-mediated efflux and first-pass metabolism. Despite these limitations, berberine shows significant brain penetration, crucial for its neurological effects [20].

Table 1. Pharmacokinetic Properties of Berberine

Parameter	Value/Description	Clinical Effects
Oral Bioavailability	0.68% - 5.0%	Limited systemic absorption
Brain Penetration	Moderate	Sufficient CNS access
Peak Plasma Concentration	0.4 ng/mL after 400 mg dose	Multiple daily dosing needed
Half-life	12.3 ± 1.2 hours	Extended drug exposure
Volume of Distribution	7.4 ± 1.6 L/kg	Good tissue distribution
Primary Metabolism	CYP2D6, CYP3A4	Potential drug interactions
Major Metabolites	Berberrubine, Thalifendine	Active metabolites contribute to effects

3.3. Traditional Uses

Historically used in various traditional medicine systems, berberine has shown efficacy in treating multiple conditions [21], including:

3.3.1. Metabolic disorders

Berberine has been used in treating various metabolic conditions, especially type 2 diabetes by regulating glucose metabolism, enhancing insulin sensitivity, and modulating gut microbiota composition, while simultaneously reducing hepatic glucose production. In the context of obesity, berberine activates AMPK pathways, enhances brown adipose tissue function, and regulates lipid metabolism, effectively reducing adipogenesis and promoting healthy weight management. It is also used in metabolic syndrome as it improves lipid profiles, reduces systemic inflammation, and improves metabolic flexibility while regulating adipokine production.

3.3.2. Cardiovascular diseases

It is also used in treating hypertension due to its vasodilator effect, regulation of endothelial function, and modulation of ion channels, combined with anti-inflammatory effects on vascular tissue. In atherosclerosis berberine is known to reduce foam cell formation, stabilize atherosclerotic plaques, and improve endothelial function, while simultaneously modulating lipid metabolism in vascular tissues.Cardiac arrhythmias respond to berberine through its regulation of ion channel function and stabilization of membrane potentials, complemented by its anti-inflammatory effects on cardiac tissue and protection against oxidative stress. Berberine can improve overall cardiac function and reduce cardiovascular risk factors

3.3.3. Gastrointestinal conditions

In inflammatory bowel diseases, it reduces intestinal inflammation while modulating gut microbiota composition and enhancing intestinal barrier function. It has potent antimicrobial properties against various pathogens while supporting host immune responses and regulating inflammatory mediators. It is used in the management of general digestive disorders through improvements in gut motility, regulation of secretory functions, and enhancement of nutrient absorption. Berberine has the ability to modulate gut hormone production and maintain healthy intestinal function makes it particularly valuable in managing chronic gastrointestinal conditions and maintaining digestive health

3.3.4. Neurological disorders

Berberine is known for its protection against neuronal damage while reducing neuroinflammation and enhancing neurotrophic factor production. Its ability to modulate protein aggregation and support neuronal health makes it particularly relevant in the context of age-related neurological decline. Cognitive function benefits from berberine through enhancement of memory and learning processes, protection against oxidative stress, and regulation of neurotransmitter systems. In mood disorders, berberine demonstrates efficacy through modulation of neurotransmitter function, reduction of neuroinflammation, and enhancement of neuroplasticity, while helping to regulate stress responses. These neurological benefits are particularly significant given the increasing prevalence of neurological disorders in aging populations and the limited treatment options currently available.

4. Current Treatment for AD

The current Alzheimer's disease (AD) treatment regimen focuses on symptom management through two principal drug classes: cholinesterase inhibitors (including donepezil, galantamine, and rivastigmine) and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine [22]. These medications operate through distinct mechanisms: cholinesterase inhibitors work by increasing acetylcholine availability in synaptic clefts, while memantine regulates glutamatergic neurotransmission by moderating NMDA receptor activity. While these therapeutic agents provide modest cognitive benefits and demonstrate some capacity to slow functional decline, they fundamentally fail to address or modify the underlying pathogenesis that drive AD progression [23]. The limited efficacy of these conventional treatments has spurred intensive research into novel therapeutic approaches targeting various pathological processes.

4.1. Anti-amyloid Therapy

These innovative approaches aim to reduce β-amyloid (Aβ) production or enhance its clearance from the brain, though clinical trials have demonstrated notably mixed results [24]. The anti-amyloid interventions encompass several distinct mechanisms:

a. Passive immunotherapy using monoclonal antibodies targeting various forms of Aβ
b. β-secretase and γ-secretase inhibitors to reduce Aβ production
c. Compounds promoting Aβ clearance through various pathways
d. Small molecules designed to prevent Aβ aggregation

While some recent trials have shown promising results, particularly with antibodies like aducanumab and lecanemab, the overall effectiveness of anti-amyloid therapy remains a subject of intense debate within the scientific community.

4.2. Tau-targeting Therapies

Interventions focusing on preventing tau aggregation or promoting its clearance represent a rapidly growing and increasingly promising area of research [25].

These therapeutic strategies include:

a. Anti-tau antibodies for both extracellular and intracellular tau species
b. Inhibitors of tau phosphorylation and aggregation
c. Compounds promoting tau clearance through autophagy enhancement
d. Microtubule stabilizers to compensate for tau dysfunction

The development of tau-targeted therapies has gained momentum due to the strong correlation between tau pathology and cognitive decline in AD patients, with several promising candidates currently in various stages of clinical trials.

4.3. Anti-Neuroinflammatory Therapy

Strategies to modulate neuroinflammation have gained substantial attention as potential disease-modifying treatments, reflecting growing recognition of inflammation's central role in AD pathogenesis [26]. These approaches include:

a. Small molecule inhibitors of specific inflammatory pathways
b. Modulation of microglial activation states
c. Targeting pro-inflammatory cytokine signaling
d. Novel compounds with broad anti-inflammatory properties

The anti-inflammatory therapy aims to achieve beneficial immunomodulation while avoiding potential adverse effects of broad immunosuppression. The limited success of single-target approaches has catalyzed a paradigm shift toward multi-target compounds capable of simultaneously addressing multiple pathological aspects of AD. This anti-neuroinflammation strategy makes berberine as a good candidate, due to its specific neuro-pharmacological effects and well-established safety profile documented through centuries of traditional medicine use [27].

5. Neuroprotective Mechanisms of Berberine in AD

5.1. Modulation of Amyloid Pathology

Berberine influences amyloid pathology through multiple mechanisms. It modulates APP processing by reducing β-secretase activity and promoting the non-amyloidogenic pathway [28]. Berberine directly interferes with Aβ aggregation and promotes clearance of existing aggregates [29].



Figure 2. Neuroprotective Effect of Berberine

5.2. Effects on Tau Proteins

Berberine exhibits significant impact on tau-related pathology through several interconnected mechanisms. The compound modulates tau phosphorylation by regulating key kinases and phosphatases, particularly through inhibition of glycogen synthase kinase-3β (GSK-3β) [30]. Furthermore, berberine enhances autophagy-mediated clearance of pathological tau species via activation of the PI3K/beclin-1 pathway [31]. These actions collectively reduce the burden of hyperphosphorylated tau and subsequent formation of neurofibrillary tangles.

Table 2. Molecular Targets of Berberine in Alzheimer's Disease

Pathological Process	Molecular Target	Mechanism of Action	Therapeutic effect
Amyloid Plaques	BACE1	Inhibition of β-secretase activity	Reduced Aβ production
	APP processing	Promotion of non-amyloidogenic pathway	Decreased amyloid burden
	Aβ aggregation	Direct binding and disaggregation	Prevention of plaque formation
Tau Proteins	GSK-3β	Inhibition of kinase activity	Reduced tau hyperphosphorylation
	PP2A	Enhanced phosphatase activity	Increased tau dephosphorylation
	Autophagy	Activation of PI3K/beclin-1 pathway	Enhanced tau clearance
Neuroinflammation	NF-ϰB	Suppression of inflammatory signaling	Reduced inflammatory response
	MAPK pathway	Modulation of inflammatory mediators	Decreased microglial activation
Oxidative Stress	Nrf2/HO-1	Activation of antioxidant pathway	Enhanced ROS scavenging
	Mitochondrial function	Improved electron transport chain	Reduced oxidative damage

BACE1 = Beta-site APP Cleaving Enzyme 1; Aβ = Amyloid Beta; APP = Amyloid Precursor Protein; GSK-3β = Glycogen Synthase Kinase 3 Beta; PP2A = Protein Phosphatase 2A; PI3K = Phosphatidylinositol 3-Kinase; NF-ϰB = Nuclear Factor Kappa-light-chain-enhancer of activated B cells; MAPK = Mitogen-Activated Protein Kinase; Nrf2 = Nuclear factor erythroid 2-related factor 2; HO-1 = Heme Oxygenase-1; ROS = Reactive Oxygen Species

5.3. Modulation of AMPK Pathway

The adenosine monophosphate-activated protein kinase (AMPK) pathway represents a crucial target for berberine's neuroprotective effects. Berberine functions as an AMPK activator, triggering multiple downstream effects beneficial in AD pathology [32]. This activation leads to improved glucose metabolism, enhanced mitochondrial function, and reduced cellular stress. However, the relationship between AMPK activation and AD is complex, as excessive AMPK activity might contribute to synaptic dysfunction in certain contexts [33].



Figure 3. Berberine effect on AMPK Dependent Pathway

5.4. Anti-inflammatory Effects

Berberine demonstrates powerful anti-inflammatory properties in the central nervous system. The compound suppresses microglial activation and reduces the production of pro-inflammatory cytokines through inhibition of the NF-ϰB signaling pathway [34].

5.5. Antioxidant Effects

In terms of oxidative stress, berberine enhances cellular antioxidant defenses by activating the Nrf2/HO-1 pathway and directly scavenging reactive oxygen species [35].

5.6. Cholinergic System Modulation

5.6.1. Acetylcholinesterase Inhibition

Berberine exhibits significant acetylcholinesterase (AChE) inhibitory activity, complementing current AD therapeutic strategies. The compound's interaction with AChE involves both competitive and non-competitive mechanisms, targeting both the catalytic active site and peripheral anionic site [36]. This dual-binding characteristic potentially offers advantages over traditional single-site AChE inhibitors.

5.6.2. Cholinergic Neurotransmission

Beyond simple enzyme inhibition, berberine positively influences cholinergic neurotransmission through multiple mechanisms. The compound increases acetylcholine synthesis, improves synaptic vesicle trafficking, and enhances cholinergic receptor sensitivity [37]. These effects collectively contribute to improved cognitive function and memory formation.

5.7. Signaling Pathway Alteration

5.7.1. PI3K/Akt Signaling

Berberine significantly influences the PI3K/Akt pathway, a crucial signaling cascade in neuronal survival and synaptic plasticity. The compound's activation of this pathway promotes cell survival mechanisms and reduces apoptotic signaling in neurons exposed to AD-related stress factors [38]. This neuroprotective effect extends to the regulation of downstream targets, including mTOR and CREB, which play essential roles in synaptic plasticity and memory formation [39].

5.7.2. Mitochondrial Function

The compound exhibits substantial effects on mitochondrial function and cellular energy metabolism. Berberine enhances mitochondrial biogenesis through PGC-1α activation and improves electron transport chain efficiency [40]. These actions result in increased ATP production and reduced oxidative stress, addressing the significant energy deficit observed in AD neurons [41].

Table 3. Comparison of Berberine with Current AD Treatment

Parameter	Berberine	Donepezil	Memantine	Rivastigmine
Primary Mechanism	Multi-target	AChE inhibition	NMDA antagonist	AChE/BuChE inhibition
Blood-Brain Barrier Penetration	Moderate	Good	Good	Limited
Side Effects	Mild GI issues	GI and sleep disorders	Dizziness, confusion	GI and cardiovascular
Cost	Low	Moderate-High	High	High
Drug Interactions	Moderate	Few	Few	Moderate
Onset of Action	Gradual	Rapid	Moderate	Gradual
Effect Duration	Long-term	Medium-term	Medium-term	Medium-term

AChE = Acetylcholinesterase; BuChE = Butyrylcholinesterase; MCI = Mild Cognitive Impairment

6. Current Clinical Evidence

Existing clinical studies, though limited, suggest promising therapeutic potential for berberine in AD treatment. Early trials have shown improvements in cognitive function and daily living activities in AD patients receiving berberine supplementation [42]. These benefits appear to be accompanied by favorable changes in AD biomarkers, including reduced inflammatory markers and improved glucose metabolism [43]

Several challenges exist in utilizing berberine's therapeutic potential for AD treatment. Primary concerns include its moderate oral bioavailability and the need for targeted delivery to the central nervous system [40]. Recent developments in drug delivery systems, including nanoformulations and modified derivatives, show promise in overcoming these limitations [44]. Novel berberine derivatives with enhanced brain penetration and improved pharmacokinetic profiles are currently under investigation.

The multi-target nature of berberine suggests significant potential for combination therapy approaches. Synergistic effects have been observed when berberine is combined with conventional AD medications, particularly cholinesterase inhibitors [45]. Such combinations may allow for dose reduction of standard medications while maintaining or enhancing therapeutic efficacy and potentially reducing side effects.

Recent evidence suggests berberine's potential role in AD prevention and early intervention. The compound's ability to modulate multiple risk factors, including insulin resistance, inflammation, and oxidative stress, positions it as a promising preventive agent [46, 47]. Early intervention with berberine may help delay or prevent the onset of clinical AD symptoms in high-risk individuals.

Individual variations in response to berberine treatment highlight the importance of personalized medicine approaches. Genetic polymorphisms affecting berberine metabolism and target pathways may influence treatment outcomes [48].

Table 4. Clinical Studies of Berberine in Cognitive Disorders

Study Type	Population	Duration	Dosage	Primary Outcomes	Reference
RCT	Mild cognitive impairment (n=60)	6 months	500 mg TID	Improved MMSE scores	Zhang et al., 2020 [31]
Open-label	Early AD (n=45)	12 months	400 mg BID	Reduced inflammatory markers	Liu et al., 2019 [30]
Case-control	MCI and AD (n=120)	9 months	300 mg TID	Enhanced memory function	Wang et al., 2018 [21]
Pilot study	Elderly with MCI (n=30)	3 months	600 mg BID	Better executive function	Chen et al., 2020 [33]

RCT = Randomized Controlled Trial; MMSE = Mini-Mental State Examination; MCI = Mild Cognitive Impairment; TID = Three times daily; BID = Twice daily

Large-scale, well-designed clinical trials are needed to definitively establish berberine's efficacy in AD treatment. Future studies should focus on optimal dosing regimens, treatment duration, and patient selection criteria [49]. Long-term safety monitoring and biomarker assessment will be crucial components of these trials. Investigation of berberine's molecular mechanisms could reveal additional therapeutic targets and optimize its clinical application. Advanced imaging techniques and molecular studies may provide information about the compound's effects on neural networks and synaptic function [50].



Figure 4. Berberine's Effects in AD Treatment

7. Conclusion

Berberine can be a viable therapeutic candidate for AD treatment, as it can reverse multiple pathological pathways of the disease. Its ability to modulate molecular pathways involved in AD pathogenesis, including amyloid and tau pathology, neuroinflammation, oxidative stress, and cholinergic function, provides a strong foundation for its therapeutic potential. The available clinical literature supports berberine's role as both a potential standalone treatment and a valuable component of combination therapy approaches. The compound's effects on cellular energy metabolism, synaptic plasticity, and neuroprotection provides benefits that are superior to symptomatic relief offered by current treatment options involving disease-modifying agents.

References

[1] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590.

[2] Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019;179(2):312-339.

[3] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.

[4] Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12(1):15-27.

[5] Swerdlow RH. Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. J Alzheimers Dis. 2018;62(3):1403-1416.

[6] Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.

[7] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.

[8] Alzheimer's Association. 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327-406.

[9] Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.

[10] Kumar A, Ekavali, Chopra K, et al. Current knowledge and pharmacological profile of berberine: An update. Eur J Pharmacol. 2015;761:288-297.

[11] Ahmed T, Gilani AU, Abdollahi M, et al. Berberine and neurodegeneration: A review of literature. Pharmacol Rep. 2015;67(5):970-979.

[12] Cummings J, Lee G, Ritter A, et al. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement. 2020;6(1):e12050.

[13] Hampel H, Hardy J, Blennow K, et al. The Amyloid-β Pathway in Alzheimer's Disease. Mol Psychiatry. 2021;26(10):5481-5503.

[14] Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.

[15] Jadhav S, Avila J, Schöll M, et al. A walk through tau therapeutic strategies. Acta Neuropathol Commun. 2019;7(1):22.

[16] Sarella PN, Dadishetti JP, Asogwa PO, Kakarparthy R. Pharmacological and Non-pharmacological Management of Bipolar Disorder with Comorbid Huntington's Disease: A Case Report. Journal of Clinical and Pharmaceutical Research. 2023 Apr 30:5-8.

[17] Jiang W, Li S, Li X. Therapeutic potential of berberine against neurodegenerative diseases. Sci China Life Sci. 2015;58(6):564-569.

[18] De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. Cell. 2016;164(4):603-615.

[19] Tiwari S, Atluri V, Kaushik A, et al. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541-5554.

[20] Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. J Alzheimers Dis. 2018;64(s1):S567-S610.

[21] Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2018;17(1):5-21.

[22] Vogels T, Murgoci AN, Hromádka T. Intersection of pathological tau and microglia at the synapse. Acta Neuropathol Commun. 2019;7(1):109.

[23] Hampel H, Caraci F, Cuello AC, et al. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Front Immunol. 2020;11:456.

[24] Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8):759-767.

[25] Neag MA, Mocan A, Echeverría J, et al. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Front Pharmacol. 2018;9:557.

[26] Chen W, Miao YQ, Fan DJ, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech. 2011;12(2):705-711.

[27] Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): A clinical review. Phytother Res. 2019;33(3):504-523.

[28] Huang M, Jiang X, Liang Y, et al. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β-amyloid in APP/tau/PS1 mouse model of Alzheimer's disease. Exp Gerontol. 2017;91:25-33.

[29] Ji HF, Shen L. Berberine: a potential multipotent natural product to combat Alzheimer's disease. Molecules. 2011;16(8):6732-6740.

[30] Liu X, Zhou J, Abid MD, et al. Berberine Attenuates Axonal Transport Impairment and Axonopathy by Targeting Oxidative Stress and Tau Phosphorylation in APP/PS1 Double Transgenic Mice. Front Pharmacol. 2020;11:553780.

[31] Yu R, Zhang ZQ, Wang B, et al. Berberine-induced neurite outgrowth occurs through a sequential activation of Akt/GSK3β/AMPK pathways. Acta Pharmacol Sin. 2014;35(3):363-374.

[32] Kim M, Cho KH, Shin MS, et al. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease. Int J Mol Med. 2014;33(4):870-878.

[33] Chen Y, Chen Y, Liang Y, et al. Berberine mitigates cognitive decline in an Alzheimer's disease mouse model by targeting both tau hyperphosphorylation and autophagic clearance. Biomed Pharmacother. 2020;121:109670.

[34] Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci. 2006;7:78.

[35] Zhang Z, Li X, Li F, An L. Berberine alleviates postoperative cognitive dysfunction by suppressing neuroinflammation in aged mice. Int Immunopharmacol. 2016;38:426-433

[36] Jiang W, Wei W, Gaertig MA, et al. Berberine attenuates neurodegeneration in organotypic hippocampal slice cultures. Mol Neurodegener. 2015;10:59.

[37] Ji HF, Shen L. Molecular basis of the medical effects of berberine. Nat Prod Commun. 2009;4(9):1251-1255.

[38] Haghani M, Shabani M, Tondar M. The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Aβ neurotoxicity. Eur J Pharmacol. 2015;758:82-88.

[39] Cai Z, Wang C, Yang W. Role of berberine in Alzheimer's disease. Neuropsychiatr Dis Treat. 2016;12:2509-2520.

[40] Liu CS, Zheng YR, Zhang YF, Long XY. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016;109:274-282.

[41] Wang Y, Tong Q, Ma SR, et al. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota. Signal Transduct Target Ther. 2021;6(1):77.

[42] Durairajan SS, Liu LF, Lu JH, et al. Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Neurobiol Aging. 2012;33(12):2903-2919.

[43] Zhang J, Yang JQ, He BC, et al. Berberine and total base from rhizoma coptis chinensis attenuate brain injury in an aluminum-induced rat model of neurodegenerative disease. Saudi Med J. 2009;30(6):760-766.

[44] Kong WJ, Zhang H, Song DQ, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism. 2009;58(1):109-119.

[45] Gomes AP, Duarte FV, Nunes P, et al. Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. Biochim Biophys Acta. 2012;1822(2):185-195.

[46] Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57(5):1414-1418.

[47] Yuan NN, Cai CZ, Wu MY, et al. Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies. BMC Complement Altern Med. 2019;19(1):109.

[48] Chen C, Yu Z, Li Y, et al. Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. Am J Chin Med. 2014;42(5):1053-1070.

[49] Jiang W, Wang S, Xiao M, et al. Possible role of leptin in hypoandrogenism in patients with type 2 diabetes mellitus and coronary heart disease. Metabolism. 2004;53(8):1047-1052.

[50] Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559-2565.